- Home
- MYGN vs CCRN Comparison
MYGN vs CCRN Comparison
Compare MYGN & CCRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- CCRN
- Stock Information
- Founded
- MYGN 1991
- CCRN 1986
- Country
- MYGN United States
- CCRN United States
- Employees
- MYGN N/A
- CCRN N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CCRN Professional Services
- Sector
- MYGN Health Care
- CCRN Consumer Discretionary
- Exchange
- MYGN Nasdaq
- CCRN Nasdaq
- Market Cap
- MYGN 423.1M
- CCRN 447.2M
- IPO Year
- MYGN 1995
- CCRN N/A
- Fundamental
- Price
- MYGN $7.64
- CCRN $12.46
- Analyst Decision
- MYGN Hold
- CCRN Hold
- Analyst Count
- MYGN 13
- CCRN 5
- Target Price
- MYGN $13.50
- CCRN $17.93
- AVG Volume (30 Days)
- MYGN 1.4M
- CCRN 347.9K
- Earning Date
- MYGN 11-06-2025
- CCRN 11-05-2025
- Dividend Yield
- MYGN N/A
- CCRN N/A
- EPS Growth
- MYGN N/A
- CCRN N/A
- EPS
- MYGN N/A
- CCRN N/A
- Revenue
- MYGN $832,900,000.00
- CCRN $1,192,539,000.00
- Revenue This Year
- MYGN $0.17
- CCRN N/A
- Revenue Next Year
- MYGN $6.19
- CCRN N/A
- P/E Ratio
- MYGN N/A
- CCRN N/A
- Revenue Growth
- MYGN 3.83
- CCRN N/A
- 52 Week Low
- MYGN $3.76
- CCRN $9.58
- 52 Week High
- MYGN $29.30
- CCRN $18.33
- Technical
- Relative Strength Index (RSI)
- MYGN 75.45
- CCRN 38.15
- Support Level
- MYGN $6.73
- CCRN $11.09
- Resistance Level
- MYGN $7.05
- CCRN $14.30
- Average True Range (ATR)
- MYGN 0.38
- CCRN 0.64
- MACD
- MYGN 0.10
- CCRN -0.10
- Stochastic Oscillator
- MYGN 94.31
- CCRN 40.34
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About CCRN Cross Country Healthcare Inc. $0.0001 Par Value
Cross Country Healthcare Inc is a provider of total talent management services, including strategic workforce solutions, contingent staffing, permanent placement and consultative services for healthcare customers. The company operates in two business segments: the nurse and allied staffing segment, which generates a vast majority of revenue, offers temporary and permanent placements of travel and local nurses and allied professionals, and other outsourcing services.: the Physician Staffing segment provides licensed practitioners across a broad array of specialties, as well as certified registered nurse anesthetists (CRNAs), nurse practitioners (NPs), and physician assistants (PAs) on temporary assignments. The company earns majority of its revenue from the United States.